Drug Trials News for August 2018

Drug Trials News Archive

Is Mesoblast’s acute Graft versus Host Disease product poised to fulfil the promise of mesenchymal stem cells? Is Mesoblast’s acute Graft versus Host Disease product poised to fulfil the promise of mesenchymal stem cells?

The therapeutic use of mesenchymal stem cells or MSCs was first investigated in humans in 1995, generating a great deal of early enthusiasm about their promise as easily manufactured allogeneic cellular medicines. Since 1995, MSCs have become one of the most clinically studied experimental cell therapy platforms in the world. After more than 20 years of MSC clinical research, which has not yet resulted in an FDA-approved therapy, many people have questioned whether they can fulfil their therapeutic promise.